Therapeutic potential of endothelin receptor antagonism in kidney disease.

Abstract

Our growing understanding of the role of the endothelin (ET) system in renal physiology and pathophysiology is from emerging studies of renal disease in animal models and humans. ET receptor antagonists reduce blood pressure and proteinuria in chronic kidney disease and cause regression of renal injury in animals. However, the therapeutic potential of ET receptor antagonism has not been fully explored and clinical studies have been largely limited to patients with diabetic nephropathy. There remains a need for more work in nondiabetic chronic kidney disease, end-stage renal disease (patients requiring maintenance dialysis and those with a functioning kidney transplant), ischemia reperfusion injury, and sickle cell disease. The current review summarizes the most recent advances in both preclinical and clinical studies of ET receptor antagonists in the field of kidney disease.

• Authors: Alicja Czopek, Rebecca Moorhouse, David J Webb, Neeraj Dhaun
• Journal: American journal of physiology. Regulatory, integrative and comparative physiology (Am J Physiol Regul Integr Comp Physiol) Vol. 310 Issue 5 Pg. R388-97 (Mar 01 2016) ISSN: 1522-1490 [Electronic] United States
• PMID: 26702154 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2016 the American Physiological Society.

Chemical References

• Endothelin Receptor Antagonists
• Endothelins
• Ligands
• Receptors, Endothelin

Topics

• Animals
• Endothelin Receptor Antagonists (adverse effects, therapeutic use)
• Endothelins (metabolism)
• Humans
• Kidney (drug effects, metabolism, physiopathology)
• Kidney Diseases (drug therapy, metabolism, physiopathology)
• Ligands
• Receptors, Endothelin (drug effects, metabolism)
• Signal Transduction (drug effects)